ArticleBrain pathology (Zurich, Switzerland)2000
Characteristic chromosomal imbalances in primary central nervous system lymphomas of the diffuse large B-cell type.
Article in Brain pathology (Zurich, Switzerland), 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 83 citations in OpenAlex.
- MYC protein expression in primary diffuse large B-cell lymphoma of the central nervous system.PloS one · 2014Trial
- Review
- Protein tyrosine phosphatase receptor type kappa (PTPRK) revisited: evolving insights into structure, function, and pathology.Journal of translational medicine · 2025Review
- Primary central nervous system lymphoma.Nature reviews. Disease primers · 2023Review
- Intratumor heterogeneity and T cell exhaustion in primary CNS lymphoma.Genome medicine · 2022Article
- Review
- Review
- Introduction of novel agents in the treatment of primary CNS lymphoma.Neuro-oncology · 2019Review
- The Challenge of Primary Central Nervous System Lymphoma.Hematology/oncology clinics of North America · 2016Review
- YKL-40 and MMP-9 as serum markers for patients with primary central nervous system lymphoma.Annals of neurology · 2011Article
- Genetic variants of folate and methionine metabolism and PCNSL incidence in a German patient population.Journal of neuro-oncology · 2010Article
- Chromosomal imbalances and partial uniparental disomies in primary central nervous system lymphoma.Leukemia · 2009Article
- Insights into the biology of primary central nervous system lymphoma.Current oncology reports · 2009Review
- Del(6)(q22) and BCL6 rearrangements in primary CNS lymphoma are indicators of an aggressive clinical course.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2008Article
- Trisomy 19 ependymoma, a newly recognized genetico-histological association, including clear cell ependymoma.Molecular cancer · 2007Article
- Primary central nervous system lymphoma.Current treatment options in neurology · 2006Article
- Diagnosis and treatment of primary central nervous system lymphoma.Current oncology reports · 2005Review
- The methionine synthase polymorphism D919G alters susceptibility to primary central nervous system lymphoma.British journal of cancer · 2004Article
- Analysis of chromosomal copy number changes and oncoprotein expression in primary central nervous system lymphomas: frequent loss of chromosome arm 6q.Virchows Archiv : an international journal of pathology · 2003Article
- Translocation t(9;22) (p23;q11) in atypical chronic myeloid leukemia (aCML) presenting osteolytic lesions.International journal of hematology · 2002Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We performed a genome wide screening for genomic alterations on a series of 19 sporadic primary central nervous system lymphomas (PCNSL) of the diffuse large B-cell type by comparative genomic hybridization (CGH). The tumors were additionally analyzed for amplification and rearrangement of the BCL2 gene at 18q21 as well as for mutation of the recently cloned BCL10 gene at 1p22. Eighteen tumors showed genomic imbalances on CGH analysis. On average, 2.1 losses and 4.7 gains were detected per tumor. The chromosome arm most frequently affected by losses of genomic material was 6q (47%) with a commonly deleted region mapping to 6q21-q22. The most frequent gains involved chromosome arms 12q (63%), 18q and 22q (37% each), as well as 1q, 9q, 11q, 12p, 16p and 17q (26% each). High-level amplifications were mapped to 9p23-p24 (1 tumor) and to 18q21-q23 (2 tumors). However, PCR-based analysis, Southern blot analysis and high-resolution matrix-CGH of the BCL2 gene revealed neither evidence for amplification nor for genetic rearrangement. Mutational analysis of BCL10 in 16 PCNSL identified four distinct sequence polymorphisms but no mutation. Taken together, our data do not support a role of BCL2 rearrangement/amplification and BCL10 mutation in PCNSL but indicate a number of novel chromosomal regions that likely carry yet unknown tumor suppressor genes or proto-oncogenes involved in the pathogenesis of these tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.